US third-party payers will strongly embrace generic Copaxone (according to Craig Wheeler on MNTA’s webcast today) because there are currently no US generic drugs for multiple sclerosis.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”